These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. A propensity score-matched comparison between Cardia and Amplatzer PFO closure devices - insights from the SOLUTION registry (Swiss percutaneOus patent foramen ovale cLosUre in recurrent clinical events prevenTION). Puricel S; Arroyo D; Goy JJ; Praz F; Palhais N; Wahl A; Stauffer JC; Togni M; Berger A; Meier B; Cook S EuroIntervention; 2015 Jun; 11(2):230-7. PubMed ID: 24830681 [TBL] [Abstract][Full Text] [Related]
45. Treatment of Platypnea-Orthodeoxia Syndrome in a Patient with Normal Cardiac Hemodynamics: A Review of Mechanisms with Implications for Management. Porter BS; Hettleman B Methodist Debakey Cardiovasc J; 2018; 14(2):141-146. PubMed ID: 29977471 [TBL] [Abstract][Full Text] [Related]
46. Cardioembolic stroke: who is the guilty? Gaio G; Santoro G; Palladino MT; Iacono C; Castaldi B; Russo MG; Calabrò R J Cardiovasc Med (Hagerstown); 2011 May; 12(5):370-2. PubMed ID: 20613549 [TBL] [Abstract][Full Text] [Related]
51. Frequent Arterial Emboli in a Patient with Acute Pulmonary Thromboembolism and Patent Foramen Ovale. Amirfarhangi A; Zeraatian S; Hassanzadeh M Ann Vasc Surg; 2018 Nov; 53():274.e7-274.e10. PubMed ID: 30081165 [TBL] [Abstract][Full Text] [Related]
52. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis. Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929 [TBL] [Abstract][Full Text] [Related]
53. Efficiency of transcatheter patent foramen ovale closure in children after paradoxical embolism events. Wawrzyńczyk M; Gałeczka M; Karwot B; Knop M; Białkowski J Kardiol Pol; 2016; 74(4):385-9. PubMed ID: 26412471 [TBL] [Abstract][Full Text] [Related]
54. Paradoxical embolism, stroke and sclerotherapy. Parsi K Phlebology; 2012 Jun; 27(4):147-67. PubMed ID: 21890881 [TBL] [Abstract][Full Text] [Related]
55. Second device for a patent foramen ovale: life saver and psychotherapy. Meier B Catheter Cardiovasc Interv; 2010 Jul; 76(1):151-2. PubMed ID: 20578221 [No Abstract] [Full Text] [Related]
56. Patent foramen ovale and cryptogenic stroke: a complex neuro-cardio-vascular problem. Spies C; Wong M Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1455-67. PubMed ID: 19900028 [TBL] [Abstract][Full Text] [Related]
57. Patent foramen ovale (PFO): is there life before death in the presence of PFO? Seiler C Eur J Clin Invest; 2015 Aug; 45(8):875-82. PubMed ID: 26017145 [TBL] [Abstract][Full Text] [Related]
58. Percutaneous closure of patent foramen ovale with a novel FlatStent. Reiffenstein I; Majunke N; Wunderlich N; Carter P; Jones R; Sievert H Expert Rev Med Devices; 2008 Jul; 5(4):419-25. PubMed ID: 18573042 [TBL] [Abstract][Full Text] [Related]
59. Percutaneous closure of patent foramen ovale in patients with presumed paradoxical embolism: periprocedural results and midterm risk of recurrent neurologic events. Balbi M; Casalino L; Gnecco G; Bezante GP; Pongiglione G; Marasini M; Del Sette M; Barsotti A Am Heart J; 2008 Aug; 156(2):356-60. PubMed ID: 18657668 [TBL] [Abstract][Full Text] [Related]
60. Medium-term results of transcatheter closure of patent foramen ovale (PFO) with Amplatzer PFO and Cribriform occluders. Białkowski J; Wawrzyńczyk M; Karwot B; Fiszer R; Knop M; Szkutnik M Kardiol Pol; 2012; 70(11):1142-6. PubMed ID: 23180522 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]